Menu
Our Vision
We aim to empower patients for better healthcare with Artificial Intelligence.
AI in Healthcare is Our Passion
We develop advanced medical devices powered with Artificial Intelligence.
Solutions to Real Problems
We employ Artificial Intelligence for objective and clinically relevant analysis of medical images.
From Lund to New York
We are partnered with a global leader in theranostic medicine to target and treat cancer.

News!

News!

EXINI received FDA clearance for
aPROMISE in the United States
On July 27th, EXINI Diagnostics AB, was granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its digital application, aPROMISE™. aPROMISE was developed to quantify and standardize assessments of PSMA PET/CT images and will support the use of PYLARIFY® (piflufolastat F 18) in the U.S. aPROMISE is a convenient software platform that offers quantitative analysis and standardized reporting of PSMA PET/CT image assessments.

“With FDA clearance of aPROMISE, EXINI continues on the path to improve clinical management of prostate cancer patients with innovative and clinically relevant imaging biomarkers.” Aseem Anand, Vice President and Site Manager of EXINI Diagnostics AB, Sweden.
Read More
aBSI is now available in United Kingdom
The EXINI devices, aBSI and EXINI bone, are now available in the United Kingdom again. EXINI Diagnostics has performed the necessary actions to be able to provide the devices to the UK customers after Brexit. QAdvis UK Ltd has been appointed as responsible person (UKRP) in the UK. Thereby we are able to continue to provide our innovative CE marked devices aBSI and EXINI bone to our UK customers.
Read More
EXINI Diagnostics AB has
achieved MDR-certification
The new European Medical Device Regulation 2017/745 (MDR) which replaces the Medical Devices Directive (93/42/EEC) will be mandatory from May 25th 2021. EXINI Diagnostics has through hard work and dedication received our MDR-certificate through our Notified Body TÜV SÜD.

“We are proud to be certified for MDR and look forward to enhancing the care of cancer patients with digital AI-solutions”
Dr. Aseem Anand. Vice President EXINI Diagnostics AB.
Read More
EXINI’s Artificial Intelligence enabled product received FDA clearance on GE Healthcare’s XELERIS platform
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the use of EXINI’s artificial intelligence enabled automated bone scan index (aBSI) on GE Healthcare’s Xeleris platform. EXINI has entered into a global software licensing agreement with GE Healthcare for the rights to EXINI bone, a vendor neutral stand-alone variant of aBSI that is enabled with artificial intelligence. Under the terms of the non-exclusive agreement EXINI will receive tiered licensing fees per license sold.
Read More
Previous
Next

aBSI

Read about our automatic bone scan index software.

aPROMISE

Find out more about our latest product available for oncology.

Find Us at the Top of Lund

Get in contact with us.

EXINI

Find out more about EXINI and what we do.

What do the experts say about the future of AI in medical imaging?

Providing a quantifiable and reproducible assessment of PSMA uptake and distribution in the body is critical here to enable precision oncology in prostate cancer.
Andrew J. Armstrong, MD.
Divisions of Medical Urology and Oncology, Duke University, NC, USA
The quantification and standardization of PSMA scan reports is a major step forward to enhance the reproducibility and timeliness of scan interpretations.
Matthew B. Rettig, MD.
Professor of medicine and urology, David Geffen School of Medicine at UCLA, CA, USA
Modern chess AI running on even modest hardware can easily defeat the greatest human grand masters. There’s no reason to think the eventual outcome will be any different with diagnostic imaging. PSMA-AI is a step towards that goal.
Stephan Probst
Chief of Nuclear Medicine, Jewish General Hospital, MontrÉal, Canada.
Artificial intelligence is essential to advance molecular imaging in cancer, to capture the power of MI for detection and quantitating molecular expression of individual tumor lesions within the prostate cancer patient.
Steven M. Larson, MD.
Department of Radiology, Memorial Sloan Kettering Cancer Center, NY, USA

EXINI Diagnostics AB

Ideon Science Park | Scheelevägen 27 | 223 70 Lund | Sweden

info@exini.com | +46 46 286 54 20 

In collaboration with:

© 2020 EXINI Diagnostics AB, a wholly owned subsidiary of Lantheus Holdings, Inc. All rights reserved. 

Trademark | Disclaimer
Privacy Policy

© 2020 EXINI Diagnostics AB, a wholly owned subsidiary of Lantheus Holdings, Inc. All rights reserved. 

Trademark | Disclaimer
Privacy Policy

Trademark

EXINI® is a Registered Trademark.

Disclaimer

The materials on this website are of a general, informational nature. The content does not purport to be exhaustive and should not be relied upon as a substitute or replacement for individual medical, technical or instructional advice on any specific matter. If you have a specific question, you are most welcome to address it to one of our representatives or through the appropriate e-mail. Links to other websites are for information only. We do not endorse or accept any responsibility or liability for the material on any website referred to or accessed through this website. All links to our website should go to the top-level page.